Ask AI

Immune Checkpoint Inhibitors in BCC and CSCC: Aligning Clinical Practice With Best Practices and Guidelines

Start Activity
Video
Video Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: November 03, 2026

Expiration: May 02, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Video 3 Post Assessment 4 Evaluation 5 Credit

In this on-demand webcast, an expert reviews the evolving role of immune checkpoint inhibitors (ICIs) in the management of basal cell carcinoma and cutaneous squamous cell carcinoma, with a focus on treatment selection, emerging clinical evidence, and toxicity management. Clinical trial and real-world data on approved PD-1 and PD-L1 inhibitors, including cemiplimab, pembrolizumab, and cosibelimab, are examined, along with evidence supporting neoadjuvant and adjuvant immunotherapy in patients with high-risk or advanced disease. Findings from key studies, including EMPOWER-CSCC-1, KEYNOTE-629, C-POST, KEYNOTE-630, and MATISSE, highlight treatment efficacy, pathologic responses, recurrence outcomes, and considerations for integrating immunotherapy with surgery and radiation. The expert also discusses recognition and management of immune-related adverse events, particularly cutaneous and endocrine toxicities, and emerging approaches such as intralesional immunotherapy, combination regimens, and response-adapted treatment strategies. Case-based discussions emphasize the importance of multidisciplinary collaboration, individualized risk assessment, and shared decision-making when incorporating ICIs into clinical practice.

Vishal Anil Patel
Vishal Anil Patel, MD
ICIs in BCC and CSCC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
Begin Your Video
1.

How many people with BCC or CSCC do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following best describes your role on the care team?

4.

Are you a member of an AAD Chapter?

5.

Patient Case: 72-Yr-Old Man With Metastatic BCC



  • A 72-yr-old man has metastatic BCC with pulmonary nodules and biopsy-proven nodal disease

  • He previously received vismodegib with an initial partial response

  • However, he now has radiographic progression and worsening fatigue, dysgeusia, and muscle cramps 

When counseling this patient, which of the following would you discuss as the next best systemic treatment approach for his symptoms? ​

6.

Patient Case: 69-Yr-Old Woman With CSCC



  • A 69-yr-old woman is diagnosed with high-risk stage III CSCC

  • She receives neoadjuvant cemiplimab but develops fatigue, anorexia, dizziness, and mild nausea several wk into treatment

  • Laboratory tests show:

    • AM cortisol: low

    • ACTH: low/inappropriately normal

    • TSH: low-normal

    • Free T4: low 



What is the next best step for this patient? ​

7.

Which of the following patients with CSCC would be the best candidate for enrollment in the phase III CLEAR-CSCC trial? ​

8.

Do you currently routinely incorporate ICIs into treatment of patients in your practice with BCC or CSCC?

Begin Your Video